<p>持有 <strong>Alector, Inc.</strong> (NASDAQ:ALEC) 股票的投资者会感到宽慰，因为在过去的三十天里，股价反弹了 27%，但它需要继续上涨，以修复近期对投资者投资组合造成的损害。然而，上个月对过去一年 76% 的股价下跌几乎没有改善。</p>
<p>尽管股价大幅上涨，但考虑到美国生物技术行业几乎一半的公司市销率（&#34;P/S&#34;）超过 9.3 倍，甚至超过 49 倍的市销率也并不罕见，Alector 目前仍然可能被视为一个强有力的买入机会，其市销率为 1.3 倍。然而，市销率可能较低是有原因的，需要进一步调查以确定是否合理。</p>
<p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
<p>查看我们对 Alector 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/249249899-ps-multiple-vs-industry-1-dark/1746443314731?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/249249899-ps-multiple-vs-industry-1-dark/1746443314731"/></p>
<p>NasdaqGS:ALEC 市销率与行业比较 2025 年 5 月 5 日</p>
<h3>Alector 最近的表现如何？</h3>
<p>最近一段时间，Alector 的表现不佳，因为其收入增长速度慢于大多数其他公司。也许市场预计当前的收入增长乏力趋势将持续，这使得市销率受到压制。如果是这样，现有股东可能会对股价未来的走势感到失望。</p>
<p>想知道分析师如何看待 Alector 的未来与行业的对比吗？在这种情况下，我们的 <strong>免费</strong> 报告是一个很好的起点。</p>
<h2>收入预测是否与低市销率相符？</h2>
<p>Alector 的市销率对于一家预计将实现非常低增长甚至收入下降的公司来说是典型的，重要的是，其表现远低于行业水平。</p>
<p>回顾过去一年，公司收入增长了 3.6%。然而，令人遗憾的是，收入从三年前的总额下降了 51%，这令人失望。因此，可以公平地说，最近的收入增长对公司来说并不理想。</p>
<p>展望未来，预计未来三年将带来减少的回报，七位分析师预计收入将每年下降 16%。与此同时，整个行业预计每年将扩张 157%，这描绘了一个不佳的前景。</p>
<p>根据这些信息，我们并不感到惊讶 Alector 的市销率低于行业水平。然而，收入萎缩不太可能在长期内导致稳定的市销率。如果公司不改善其收入增长，市销率可能会进一步下降。</p>
<h2>我们可以从 Alector 的市销率中学到什么？</h2>
<p>即使在如此强劲的价格波动之后，Alector 的市销率仍然落后于行业其他公司。通常，我们会警惕在做出投资决策时过于依赖市销率，尽管它可以揭示市场其他参与者对公司的看法。</p>
<p>显然，Alector 因其收入下滑的预期而维持低市销率。由于行业内其他公司预计收入增长，Alector 的糟糕前景证明了其低市销率。在这种情况下，很难看到股价在短期内强劲上涨。</p>
<p>还值得注意的是，我们发现了 <strong>Alector 的 3 个警告信号</strong>，您需要考虑这些因素。</p>
<p><strong>如果您对过去盈利增长稳健的公司感兴趣</strong>，您可能希望查看这份 <strong>免费</strong> 的其他盈利增长强劲且市盈率低的公司集合。</p>
<p>如果您打算交易 Alector，请在专业人士信赖的最低成本平台 Interactive Brokers 开设账户。</p>
<p>IBKR 在 200 多个国家和地区拥有客户，并可访问 160 个市场，让您可以通过一个集成账户交易股票、期权、期货、外汇、债券和基金。</p>
<p>享受无隐藏费用、无账户最低限额，外汇转换率低至 0.03%，远低于大多数经纪商提供的费用。</p>
<p>赞助内容</p>

ALEC

<p>Alector, Inc.（纳斯达克代码：ALEC）在过去一个月的股价上涨了 27%，但在过去一年中股价下跌了 76%。尽管近期反弹，但该公司的市销率（P/S）为 1.3 倍，仍然低于生物技术行业平均的 9.3 倍。Alector 的收入增长令人失望，预计在未来三年将每年下降 16%，与行业预期的 157% 的增长形成鲜明对比。这一疲软的前景导致 Alector 的低市销率，表明该股在未来的表现可能面临挑战</p>

<p>Those holding <strong>Alector, Inc.</strong> (NASDAQ:ALEC) shares would be relieved that the share price has rebounded 27% in the last thirty days, but it needs to keep going to repair the recent damage it has caused to investor portfolios. But the last month did very little to improve the 76% share price decline over the last year.</p>
<div class="lb-trans"><p>持有 <strong>Alector, Inc.</strong> (NASDAQ:ALEC) 股票的投资者会感到宽慰，因为在过去的三十天里，股价反弹了 27%，但它需要继续上涨，以修复近期对投资者投资组合造成的损害。然而，上个月对过去一年 76% 的股价下跌几乎没有改善。</p>
</div><p>Although its price has surged higher, Alector may still look like a strong buying opportunity at present with its price-to-sales (or &#34;P/S&#34;) ratio of 1.3x, considering almost half of all companies in the Biotechs industry in the United States have P/S ratios greater than 9.3x and even P/S higher than 49x aren't out of the ordinary. However, the P/S might be quite low for a reason and it requires further investigation to determine if it's justified.</p>
<div class="lb-trans"><p>尽管股价大幅上涨，但考虑到美国生物技术行业几乎一半的公司市销率（&#34;P/S&#34;）超过 9.3 倍，甚至超过 49 倍的市销率也并不罕见，Alector 目前仍然可能被视为一个强有力的买入机会，其市销率为 1.3 倍。然而，市销率可能较低是有原因的，需要进一步调查以确定是否合理。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
</div><p>Check out our latest analysis for Alector</p>
<div class="lb-trans"><p>查看我们对 Alector 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/249249899-ps-multiple-vs-industry-1-dark/1746443314731" alt="" original-src="https://images.simplywall.st/asset/chart/249249899-ps-multiple-vs-industry-1-dark/1746443314731"/></p>
<p>NasdaqGS:ALEC Price to Sales Ratio vs Industry May 5th 2025</p>
<div class="lb-trans"><p>NasdaqGS:ALEC 市销率与行业比较 2025 年 5 月 5 日</p>
</div><h3>How Has Alector Performed Recently?</h3>
<div class="lb-trans"><h3>Alector 最近的表现如何？</h3>
</div><p>Recent times haven't been great for Alector as its revenue has been rising slower than most other companies. Perhaps the market is expecting the current trend of poor revenue growth to continue, which has kept the P/S suppressed. If this is the case, then existing shareholders will probably struggle to get excited about the future direction of the share price.</p>
<div class="lb-trans"><p>最近一段时间，Alector 的表现不佳，因为其收入增长速度慢于大多数其他公司。也许市场预计当前的收入增长乏力趋势将持续，这使得市销率受到压制。如果是这样，现有股东可能会对股价未来的走势感到失望。</p>
</div><p>Keen to find out how analysts think Alector's future stacks up against the industry? In that case, our <strong>free</strong> report is a great place to start.</p>
<div class="lb-trans"><p>想知道分析师如何看待 Alector 的未来与行业的对比吗？在这种情况下，我们的 <strong>免费</strong> 报告是一个很好的起点。</p>
</div><h2>Do Revenue Forecasts Match The Low P/S Ratio?</h2>
<div class="lb-trans"><h2>收入预测是否与低市销率相符？</h2>
</div><p>Alector's P/S ratio would be typical for a company that's expected to deliver very poor growth or even falling revenue, and importantly, perform much worse than the industry.</p>
<div class="lb-trans"><p>Alector 的市销率对于一家预计将实现非常低增长甚至收入下降的公司来说是典型的，重要的是，其表现远低于行业水平。</p>
</div><p>Retrospectively, the last year delivered a decent 3.6% gain to the company's revenues. Still, lamentably revenue has fallen 51% in aggregate from three years ago, which is disappointing. Therefore, it's fair to say the revenue growth recently has been undesirable for the company.</p>
<div class="lb-trans"><p>回顾过去一年，公司收入增长了 3.6%。然而，令人遗憾的是，收入从三年前的总额下降了 51%，这令人失望。因此，可以公平地说，最近的收入增长对公司来说并不理想。</p>
</div><p>Turning to the outlook, the next three years should bring diminished returns, with revenue decreasing 16% per annum as estimated by the seven analysts watching the company. Meanwhile, the broader industry is forecast to expand by 157% per year, which paints a poor picture.</p>
<div class="lb-trans"><p>展望未来，预计未来三年将带来减少的回报，七位分析师预计收入将每年下降 16%。与此同时，整个行业预计每年将扩张 157%，这描绘了一个不佳的前景。</p>
</div><p>With this information, we are not surprised that Alector is trading at a P/S lower than the industry. However, shrinking revenues are unlikely to lead to a stable P/S over the longer term. There's potential for the P/S to fall to even lower levels if the company doesn't improve its top-line growth.</p>
<div class="lb-trans"><p>根据这些信息，我们并不感到惊讶 Alector 的市销率低于行业水平。然而，收入萎缩不太可能在长期内导致稳定的市销率。如果公司不改善其收入增长，市销率可能会进一步下降。</p>
</div><h2>What We Can Learn From Alector's P/S?</h2>
<div class="lb-trans"><h2>我们可以从 Alector 的市销率中学到什么？</h2>
</div><p>Even after such a strong price move, Alector's P/S still trails the rest of the industry. Typically, we'd caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.</p>
<div class="lb-trans"><p>即使在如此强劲的价格波动之后，Alector 的市销率仍然落后于行业其他公司。通常，我们会警惕在做出投资决策时过于依赖市销率，尽管它可以揭示市场其他参与者对公司的看法。</p>
</div><p>It's clear to see that Alector maintains its low P/S on the weakness of its forecast for sliding revenue, as expected. As other companies in the industry are forecasting revenue growth, Alector's poor outlook justifies its low P/S ratio. It's hard to see the share price rising strongly in the near future under these circumstances.</p>
<div class="lb-trans"><p>显然，Alector 因其收入下滑的预期而维持低市销率。由于行业内其他公司预计收入增长，Alector 的糟糕前景证明了其低市销率。在这种情况下，很难看到股价在短期内强劲上涨。</p>
</div><p>It is also worth noting that we have found <strong>3 warning signs for Alector</strong> that you need to take into consideration.</p>
<div class="lb-trans"><p>还值得注意的是，我们发现了 <strong>Alector 的 3 个警告信号</strong>，您需要考虑这些因素。</p>
</div><p><strong>If companies with solid past earnings growth is up your alley</strong>, you may wish to see this <strong>free</strong> collection of other companies with strong earnings growth and low P/E ratios.</p>
<div class="lb-trans"><p><strong>如果您对过去盈利增长稳健的公司感兴趣</strong>，您可能希望查看这份 <strong>免费</strong> 的其他盈利增长强劲且市盈率低的公司集合。</p>
</div><p>If you're looking to trade Alector, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.</p>
<div class="lb-trans"><p>如果您打算交易 Alector，请在专业人士信赖的最低成本平台 Interactive Brokers 开设账户。</p>
</div><p>With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.</p>
<div class="lb-trans"><p>IBKR 在 200 多个国家和地区拥有客户，并可访问 160 个市场，让您可以通过一个集成账户交易股票、期权、期货、外汇、债券和基金。</p>
</div><p>Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.</p>
<div class="lb-trans"><p>享受无隐藏费用、无账户最低限额，外汇转换率低至 0.03%，远低于大多数经纪商提供的费用。</p>
</div><p>Sponsored Content</p>
<div class="lb-trans"><p>赞助内容</p>
</div>

Alector, Inc. (NASDAQ:ALEC) 的股票上涨了 27%，尽管其股价和业务表现仍然落后于行业水平